Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 533Squamous Cell Carcinoma of Head and Neck 274Head and Neck Neoplasms 253Lung Neoplasms 238Uterine Cervical Neoplasms 178Stomach Neoplasms 168Esophageal Neoplasms 160Nasopharyngeal Carcinoma 123Urinary Bladder Neoplasms 116Esophageal Squamous Cell Carcinoma 115Neoplasms 113Small Cell Lung Carcinoma 104Breast Neoplasms 92Neoplasm Metastasis 90Ovarian Neoplasms 89Cholangiocarcinoma 76Carcinoma, Squamous Cell 76Pancreatic Neoplasms 72Biliary Tract Neoplasms 70Mesothelioma, Malignant 57Oropharyngeal Neoplasms 56Carcinoma 55Adenocarcinoma Of Esophagus 52Recurrence 47Parkinson Disease 4, Autosomal Dominant Lewy Body 47Carcinoma, Ovarian Epithelial 45Nasopharyngeal Neoplasms 41Lymphoma 41Adenocarcinoma of Lung 41Triple Negative Breast Neoplasms 38

Interventions

tislelizumab 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1olaparib 1asciminib 1Topotecan 1Sirolimus 1SAR125844 1Injections 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Malignant Solid Tumors × Cisplatin × Clear all
NCT07268040 2026-01-12

A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors

Shanghai Hengrui Pharmaceutical Co., Ltd.

Phase 2 Recruiting
400 enrolled
Other solid neoplasm

Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡